{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:00:58Z","timestamp":1789207258269,"version":"build-2803163510"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.idcr.2024.e02144","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T15:02:26Z","timestamp":1735484546000},"page":"e02144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A rare encounter: Fusarium falciformis and the challenges of ocular infection in the context of biologic therapy"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5590-622X","authenticated-orcid":false,"given":"Kelly","family":"Larimore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia R.","family":"Libertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idcr.2024.e02144_bib1","article-title":"Ocular adverse effects of therapeutic biologics","volume":"14","author":"Neves da Silva","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"issue":"6","key":"10.1016\/j.idcr.2024.e02144_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.14740\/jocmr2992w","article-title":"Combination antifungal therapy: a review of current data","volume":"9","author":"Campitelli","year":"2017","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.idcr.2024.e02144_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12281-020-00369-4","article-title":"Combination therapy for invasive fungal infections","volume":"14","author":"Livengood","year":"2020","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.idcr.2024.e02144_bib4","doi-asserted-by":"crossref","unstructured":"Montero\u00a0JA, Ruiz-Moreno\u00a0JM, Rodriguez\u00a0AE, Ferrer\u00a0C, Sanchis\u00a0E,\u00a0Alio\u00a0JL. Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy; 2006. \u3008https:\/\/doi.org\/10.1177\/112067210601600225\u3009.","DOI":"10.1177\/112067210601600225"},{"issue":"3","key":"10.1016\/j.idcr.2024.e02144_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/CMR.00113-16","article-title":"Bacterial and fungal endophthalmitis","volume":"30","author":"Durand","year":"2017","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.idcr.2024.e02144_bib6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00014-07","article-title":"Fusarium infections in immunocompromised patients","volume":"20","author":"Nucci","year":"2007","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.idcr.2024.e02144_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/1756-185X.12659","article-title":"Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: a literature review","volume":"19","author":"Downey","year":"2016","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.idcr.2024.e02144_bib8","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor \u03b2, and TNF-\u03b1: receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.idcr.2024.e02144_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.idcr.2024.e02144_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/IPC.0b013e31826ba107","article-title":"Endogenous fusarium endophthalmitis in hematologic malignancy: short case series and review of literature","volume":"21","author":"Malavade","year":"2013","journal-title":"Infect Dis Clin Pract"},{"issue":"5","key":"10.1016\/j.idcr.2024.e02144_bib11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ajo.2003.11.078","article-title":"In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens","volume":"137","author":"Marangon","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.idcr.2024.e02144_bib12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00003226-200305000-00004","article-title":"Advanced Fusarium keratitis progressing to endophthalmitis","volume":"22","author":"Dursun","year":"2003","journal-title":"Cornea"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250924002208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250924002208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T05:56:24Z","timestamp":1744523784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250924002208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":12,"alternative-id":["S2214250924002208"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2024.e02144","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rare encounter: Fusarium falciformis and the challenges of ocular infection in the context of biologic therapy","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2024.e02144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e02144"}}